Similarly, CTIM-76 is undergoing phase I/II investigation in patients with platinum-resistant ovarian cancer and other CLDN6-positive advanced solid tumors, including endometrial cancer (NCT06515613). Here, CLDN6 is linked to ovarian carcinoma.